

Lori A Erickson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4151265/publications.pdf>

Version: 2024-02-01

139
papers

3,254
citations

236925

25
h-index

155660

55
g-index

140
all docs

140
docs citations

140
times ranked

3330
citing authors

#	ARTICLE	IF	CITATIONS
1	Desmoid Tumor and Multiple Colon Adenomas. Mayo Clinic Proceedings, 2022, 97, 193-195.	3.0	0
2	Hemochromatosis. Mayo Clinic Proceedings, 2022, 97, 423-424.	3.0	0
3	Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocrine Pathology, 2022, 33, 64-89.	9.0	96
4	The Next Steps for Endocrine Pathology. Endocrine Pathology, 2022, 33, 228-230.	9.0	2
5	Renal Cell Carcinoma With Combined Loss of Fumarate Hydratase and SMARCB1/INI-1. Mayo Clinic Proceedings, 2022, 97, 630-632.	3.0	1
6	Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocrine Pathology, 2022, 33, 155-196.	9.0	87
7	Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Endocrine Pathology, 2022, 33, 197-227.	9.0	24
8	STAT6 Immunopositivity in Solitary Fibrous Tumor of Thyroid Gland. Mayo Clinic Proceedings, 2022, 97, 808-810.	3.0	1
9	Papillary Renal Cell Carcinoma With "Drop Metastasis" (Tumor Seeding) Involving the Distal Ureter. Mayo Clinic Proceedings, 2022, 97, 1026-1028.	3.0	1
10	Pathology data set for reporting parathyroid carcinoma and atypical parathyroid neoplasm: recommendations from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 73-82.	2.0	23
11	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 50-61.	2.0	18
12	Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice. Endocrine Pathology, 2021, 32, 17-34.	9.0	34
13	Papillary Thyroid Carcinoma BRAF Immunopositivity. Mayo Clinic Proceedings, 2021, 96, 267-268.	3.0	1
14	Pheochromocytoma in Multiple Endocrine Neoplasia Type 2. Mayo Clinic Proceedings, 2021, 96, 511-512.	3.0	0
15	Paratesticular Papillary Cystadenoma of the Epididymis in the Setting of von Hippel-Lindau. Mayo Clinic Proceedings, 2021, 96, 828-829.	3.0	4
16	Juvenile Papillomatosis of Breast. Mayo Clinic Proceedings, 2021, 96, 1097-1098.	3.0	0
17	Angiosarcoma of the Adrenal Gland. Mayo Clinic Proceedings, 2021, 96, 1376-1378.	3.0	0
18	Primary Renal Well-Differentiated Neuroendocrine Tumor (Carcinoid) in a Horseshoe Kidney. Mayo Clinic Proceedings, 2021, 96, 1687-1688.	3.0	2

#	ARTICLE	IF	CITATIONS
19	Anaplastic Thyroid Carcinoma. Mayo Clinic Proceedings, 2021, 96, 2008-2011.	3.0	5
20	Sebaceous Carcinoma. Mayo Clinic Proceedings, 2021, 96, 2285-2287.	3.0	2
21	Metaplastic Breast Cancer. Mayo Clinic Proceedings, 2021, 96, 2498-2499.	3.0	2
22	Renal Neoplasia in Hyperparathyroidism—Jaw Tumor Syndrome. Mayo Clinic Proceedings, 2021, 96, 2730-2731.	3.0	3
23	Eccrine angiomatous hamartoma: First case in the cytology literature. Annals of Diagnostic Pathology, 2021, 54, 151796.	1.3	0
24	BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance). Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 1012-1020.	2.4	4
25	Uterine Epithelioid Trophoblastic Tumor. Mayo Clinic Proceedings, 2021, 96, 2925-2926.	3.0	1
26	Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia. JAMA Network Open, 2021, 4, e2132615.	5.9	4
27	Adrenal Myelolipoma. Mayo Clinic Proceedings, 2021, 96, 3186-3187.	3.0	0
28	Malignant Epithelioid Angiomyolipoma of the Kidney (Malignant Perivascular Epithelioid Cell) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	3.0	2
29	Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 115-121.	1.3	18
30	High-Grade Serous Carcinoma of the Fallopian Tube. Mayo Clinic Proceedings, 2020, 95, 2300-2301.	3.0	0
31	Renal Neoplasia in Cowden Syndrome. Mayo Clinic Proceedings, 2020, 95, 2808-2809.	3.0	5
32	Hyalinizing Trabecular Tumor of the Thyroid. Mayo Clinic Proceedings, 2020, 95, 1810-1811.	3.0	0
33	Mucinous Carcinoma of the Breast. Mayo Clinic Proceedings, 2020, 95, 2049-2050.	3.0	4
34	Fibroadenoma of the Breast. Mayo Clinic Proceedings, 2020, 95, 2573-2574.	3.0	2
35	Unique Clinical Significance of the Cribriform-Morular Variant of Papillary Thyroid Carcinoma. Mayo Clinic Proceedings, 2020, 95, 831-833.	3.0	2
36	Tuberous Sclerosis—Associated Renal Neoplasm. Mayo Clinic Proceedings, 2020, 95, 1089-1090.	3.0	1

#	ARTICLE	IF	CITATIONS
37	Correlation of novel ALK ATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. <i>Histopathology</i> , 2020, 77, 601-610.	2.9	5
38	Fibrolamellar Carcinoma. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1298-1299.	3.0	0
39	Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Mayo Clinic Proceedings</i> , 2020, 95, 619-621.	3.0	3
40	Hepatic Focal Nodular Hyperplasia. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1557-1558.	3.0	2
41	Intestinal Spirochetosis. <i>Mayo Clinic Proceedings</i> , 2020, 95, 427-428.	3.0	4
42	Spermatic Cord Liposarcoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 737-738.	3.0	0
43	Posterior Mediastinal Schwannoma (Neurilemmoma). <i>Mayo Clinic Proceedings</i> , 2019, 94, 559-560.	3.0	2
44	Uterine Leiomyoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2150-2151.	3.0	5
45	Soft Tissue Leiomyosarcoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2366-2367.	3.0	0
46	Ovarian Fibrothecoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1652-1653.	3.0	1
47	Multiple Hereditary Osteochondromas. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1388-1389.	3.0	2
48	Renal Leiomyoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1913-1914.	3.0	0
49	Gastrointestinal Stromal Tumor. <i>Mayo Clinic Proceedings</i> , 2019, 94, 373-374.	3.0	2
50	Thymoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1122-1123.	3.0	0
51	Splenic Hemangioma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 926-927.	3.0	0
52	Merkel Cell Carcinoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2602-2604.	3.0	2
53	Lipoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 176-177.	3.0	2
54	Mucinous Neoplasm of the Appendix and Pseudomyxoma Peritonei. <i>Mayo Clinic Proceedings</i> , 2018, 93, 267-268.	3.0	2

#	ARTICLE	IF	CITATIONS
55	Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance). <i>Oncologist</i> , 2018, 23, 887-e94.	3.7	23
56	Desmoid Tumor. <i>Mayo Clinic Proceedings</i> , 2018, 93, 549-550.	3.0	4
57	Progressive Multifocal Leukoencephalopathy. <i>Mayo Clinic Proceedings</i> , 2018, 93, 123-125.	3.0	0
58	Perihilar Cholangiocarcinoma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 397-398.	3.0	5
59	NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab±everolimus for metastatic melanoma. <i>Cancer</i> , 2018, 124, 537-545.	4.1	27
60	Challenges in surgical pathology of adrenocortical tumours. <i>Histopathology</i> , 2018, 72, 82-96.	2.9	53
61	Intracholecystic Papillary-Tubular Neoplasm of the Gallbladder. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1883-1884.	3.0	0
62	Endometrial Adenocarcinoma, Endometrioid Type. <i>Mayo Clinic Proceedings</i> , 2018, 93, 963-964.	3.0	3
63	Classic Hodgkin Lymphoma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1692-1693.	3.0	0
64	Solitary Lung Nodule. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1533-1534.	3.0	0
65	Diabetic Mastopathy. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1334-1335.	3.0	0
66	Clear Cell Renal Cell Carcinoma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 813-814.	3.0	3
67	Lung Adenocarcinoma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1153-1154.	3.0	1
68	Adenocarcinoma of the Colon and Microsatellite Instability. <i>Mayo Clinic Proceedings</i> , 2018, 93, 669-670.	3.0	5
69	Immunohistochemistry in Diagnostic Parathyroid Pathology. <i>Endocrine Pathology</i> , 2018, 29, 113-129.	9.0	78
70	Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. <i>Oncotarget</i> , 2018, 9, 30268-30278.	1.8	49
71	Editorial: Special Issue on Immunohistochemical Biomarkers in Endocrine Pathology. <i>Endocrine Pathology</i> , 2018, 29, 89-90.	9.0	1
72	Testicular Seminoma. <i>Mayo Clinic Proceedings</i> , 2017, 92, e21-e22.	3.0	0

#	ARTICLE	IF	CITATIONS
73	Branchial Cleft Cyst in Lateral Neck of an Adult. Mayo Clinic Proceedings, 2017, 92, e69-e70.	3.0	1
74	Mantle Cell Involvement of the Spleen. Mayo Clinic Proceedings, 2017, 92, e81-e82.	3.0	0
75	Gastric Signet Ring Cell Carcinoma. Mayo Clinic Proceedings, 2017, 92, e95-e96.	3.0	3
76	Cervical Minimal Deviation Adenocarcinoma in Peutz-Jeghers Syndrome. Mayo Clinic Proceedings, 2017, 92, e7-e8.	3.0	1
77	Pleomorphic Adenoma in the Parotid Gland. Mayo Clinic Proceedings, 2017, 92, e55-e56.	3.0	5
78	Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review. Endocrine Pathology, 2017, 28, 293-301.	9.0	50
79	Pancreatic Ductal Adenocarcinoma. Mayo Clinic Proceedings, 2017, 92, 1461-1462.	3.0	2
80	Familial disorders of parathyroid glands. Diagnostic Histopathology, 2017, 23, 359-365.	0.4	0
81	Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase. Endocrine Pathology, 2017, 28, 269-275.	9.0	15
82	Hepatocellular Carcinoma. Mayo Clinic Proceedings, 2017, 92, 1321-1322.	3.0	0
83	Renal Pyelocalyceal Squamous Cell Carcinoma. Mayo Clinic Proceedings, 2017, 92, 1603-1604.	3.0	2
84	Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127). Endocrine Pathology, 2017, 28, 253-268.	9.0	18
85	Squamous Cell Carcinoma of the Tongue. Mayo Clinic Proceedings, 2017, 92, 1171-1172.	3.0	2
86	Gestational Trophoblastic Disease. Mayo Clinic Proceedings, 2017, 92, 1739-1740.	3.0	2
87	Ductal Carcinoma in Situ of the Breast. Mayo Clinic Proceedings, 2017, 92, 1873-1874.	3.0	0
88	Co-occurrence of steatocystoma multiplex, eruptive vellus hair cysts, and trichofolliculomas. Cutis, 2017, 100, E23-E26.	0.3	0
89	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	3.7	75
90	Paratesticular Adenomatoid Tumor. Mayo Clinic Proceedings, 2016, 91, e167-e168.	3.0	3

#	ARTICLE	IF	CITATIONS
91	Man With Fever and Severe Diarrhea. Mayo Clinic Proceedings, 2016, 91, e55-e56.	3.0	0
92	Pancoast Tumor of the Lung. Mayo Clinic Proceedings, 2016, 91, e69-e70.	3.0	4
93	Diffuse Large B-cell Lymphoma of the Testis. Mayo Clinic Proceedings, 2016, 91, e131-e132.	3.0	1
94	Sacral Chordoma. Mayo Clinic Proceedings, 2016, 91, e143-e144.	3.0	0
95	Malignant Pleural Mesothelioma. Mayo Clinic Proceedings, 2016, 91, e103-e104.	3.0	0
96	Alzheimer Disease. Mayo Clinic Proceedings, 2016, 91, e117-e118.	3.0	2
97	Results of <scp>NCCTG</scp> N0275 (Alliance) â€“ a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. Cancer Medicine, 2016, 5, 1890-1896.	2.8	18
98	Frozen section analysis of SLNs in trunk and extremity melanoma has a high false negative rate but can spare some patients a second operation. Journal of Surgical Oncology, 2016, 114, 879-883.	1.7	4
99	Parkinson Disease. Mayo Clinic Proceedings, 2016, 91, e155-e156.	3.0	2
100	Urinary Bladder Paragangliomas: Analysis of Succinate Dehydrogenase and Outcome. Endocrine Pathology, 2016, 27, 243-252.	9.0	11
101	An Adult Male With Hypophosphatemic Osteomalacia. Mayo Clinic Proceedings, 2016, 91, e81-e82.	3.0	0
102	Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index. Endocrine Pathology, 2016, 27, 259-267.	9.0	18
103	Young Female Patient With a Hepatic Adenoma: Determining Risk for Malignant Transformation. Mayo Clinic Proceedings, 2016, 91, e29-e30.	3.0	0
104	Diagnosing a Kidney Tumor. Mayo Clinic Proceedings, 2016, 91, e41-e42.	3.0	0
105	Pancreatic Tumor in a Patient With Parathyroid and Pituitary Disease. Mayo Clinic Proceedings, 2016, 91, e17-e18.	3.0	0
106	Endocrine Pathology. , 2016, , 975-1026.		1
107	Analysis of Amyloid in Medullary Thyroid Carcinoma by Mass Spectrometry-Based Proteomic Analysis. Endocrine Pathology, 2015, 26, 291-295.	9.0	25
108	Adrenocortical Carcinoma. Advances in Anatomic Pathology, 2014, 21, 151-159.	4.3	42

#	ARTICLE	IF	CITATIONS
109	Atlas of Endocrine Pathology. , 2014, , .		4
110	Diameter of dysplastic nevi is a more robust biomarker of increased melanoma risk than degree of histologic dysplasia: A case-control study. Journal of the American Academy of Dermatology, 2014, 71, 1257-1258.e4.	1.2	23
111	Incidental Findings in Medical Imaging and Genetic Testing: Opportunities and Challenges. Mayo Clinic Proceedings, 2014, 89, 715-717.	3.0	2
112	Parathyroid Carcinoma. , 2014, , 131-138.		0
113	Adrenal Cortical Carcinoma. , 2014, , 173-182.		0
114	Pheochromocytoma and Adrenal Medullary Hyperplasia. , 2014, , 187-195.		0
115	Adrenal Cysts. , 2014, , 155-157.		0
116	Endocrine Pathology. , 2011, , 903-953.		4
117	Metastatic malignant melanoma manifesting as an intracardiac mass. Cardiovascular Pathology, 2010, 19, 153-157.	1.6	14
118	Cutaneous Neuroendocrine Tumors. , 2010, , 447-452.		0
119	Familial disorders of the parathyroid gland. Diagnostic Histopathology, 2009, 15, 79-86.	0.4	6
120	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 364-380.	3.0	291
121	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 364-380.	3.0	331
122	Clinicopathologic features and BRAFV600E mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. Cancer, 2007, 109, 1965-1971.	4.1	17
123	Parathyroid Lipoadenomas: A Rare Cause of Primary Hyperparathyroidism. Endocrine Practice, 2006, 12, 131-136.	2.1	36
124	RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Laboratory Investigation, 2005, 85, 1065-1075.	3.7	104
125	Cdx2 as a Marker for Neuroendocrine Tumors of Unknown Primary Sites. Endocrine Pathology, 2004, 15, 247-252.	9.0	88
126	Cystic adrenal neoplasms. Cancer, 2004, 101, 1537-1544.	4.1	151

#	ARTICLE	IF	CITATIONS
127	Practical Markers Used in the Diagnosis of Endocrine Tumors. <i>Advances in Anatomic Pathology</i> , 2004, 11, 175-189.	4.3	89
128	Malignant Basomelanocytic Tumor Manifesting as Metastatic Melanoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1393-1396.	3.7	53
129	Analysis of Parathyroid Neoplasms by Interphase Fluorescence In Situ Hybridization. <i>American Journal of Surgical Pathology</i> , 2004, 28, 578-584.	3.7	19
130	Merkel cell carcinomas: expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers. <i>Endocrine Pathology</i> , 2003, 14, 221-229.	9.0	8
131	Merkel Cell Carcinomas: Expression of S-Phase Kinase-Associated Protein 2 (Skp2), p27, and Proliferation Markers. <i>Endocrine Pathology</i> , 2003, 14, 221-230.	9.0	2
132	Oxyphil Parathyroid Carcinomas. <i>American Journal of Surgical Pathology</i> , 2002, 26, 344-349.	3.7	65
133	Thyroid Transcription Factor-1 Distinguishes Metastatic Pulmonary From Well-Differentiated Neuroendocrine Tumors of Other Sites. <i>American Journal of Surgical Pathology</i> , 2001, 25, 815-819.	3.7	175
134	Pathologic Features and Expression of Insulin-like Growth Factor-2 in Adrenocortical Neoplasms. <i>Endocrine Pathology</i> , 2001, 12, 429-436.	9.0	41
135	p27 ^{kip1} and Other Cell-Cycle Protein Expression in Normal and Neoplastic Endocrine Tissues. <i>Endocrine Pathology</i> , 2000, 11, 109-122.	9.0	7
136	Pathologic Features, Proliferative Activity, and Cyclin D1 Expression in Hurthle Cell Neoplasms of the Thyroid. <i>Modern Pathology</i> , 2000, 13, 186-192.	5.5	70
137	p27 ^{kip1} Expression Distinguishes Papillary Hyperplasia in Graves' Disease from Papillary Thyroid Carcinoma. <i>Modern Pathology</i> , 2000, 13, 1014-1019.	5.5	47
138	p27 ^{kip1} : A Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human Cancers. <i>American Journal of Pathology</i> , 1999, 154, 313-323.	3.8	540
139	Parathyroid Hyperplasia, Adenomas, and Carcinomas. <i>American Journal of Surgical Pathology</i> , 1999, 23, 288-295.	3.7	127